Alyeska Investment Group
BDTX icon

Alyeska Investment Group’s Black Diamond Therapeutics BDTX Stock Holding History

Alyeska Investment Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-21,591
Closed -$910K – 469
2020
Q2 		$910K Buy
+21,591
New +$795K 0.01% 408

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alyeska Investment Group's BDTX Position: Q3 2020 in Review

Alyeska Investment Group sold out of Black Diamond Therapeutics (BDTX) in Q3 2020, closing a stake of 21,591 shares — an estimated $910K sold.

Alyeska Investment Group first reported a position in BDTX in Q2 2020 and held it in 1 quarter. The position peaked at $910K in Q2 2020. 88 funds tracked by Wall St. Rank hold BDTX as of Q3 2020.

  • Alyeska Investment Group reported no remaining Black Diamond Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Alyeska Investment Group sold 21,591 Black Diamond Therapeutics shares in Q3 2020, an estimated $910K.
  • Alyeska Investment Group first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 1 quarter.
  • Alyeska Investment Group's Black Diamond Therapeutics position peaked at $910K in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2020.

Based on Alyeska Investment Group's 13F filing for Q3 2020, filed 16 Nov 2020.